SCHEMBL2226029

SCHEMBL2226029

O=c1cc[nH]c2ncncc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.44
ADORA1 P30542 1/20 0.44
CCR8 P51685 1/20 0.42
KMT2A Q03164 1/20 0.41
AXL P30530 2/20 0.41
PRKCI P41743 2/20 0.41
RPS6KA5 O75582 1/20 0.40
JAK2 O60674 1/20 0.40
TTBK1 Q5TCY1 3/20 0.39
TTBK2 Q6IQ55 3/20 0.39
JAK3 P52333 2/20 0.38
NOTUM Q6P988 1/20 0.37
IKBKB O14920 1/20 0.37
CHUK O15111 1/20 0.37
DYRK1A Q13627 1/20 0.37
NUDT1 P36639 2/20 0.37
TRPA1 O75762 1/20 0.37
CCNT1 O60563 1/20 0.36
CCNA2 P20248 1/20 0.36
CDK2 P24941 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29381263 1.00 ADORA2A (0.44) ADORA2AADORA1CCR8KMT2AAXL
Trifluoroacetic Acid SCHEMBL29486292 0.86 NOTUM (0.39) ADORA2AADORA1JAK2TTBK1TTBK2
SCHEMBL14697441 0.73 CCR8 (0.52) ADORA2AADORA1CCR8KMT2AAXL
SCHEMBL12613812 0.72 PRKCI (0.43) AXLPRKCIJAK2TTBK1TTBK2
SCHEMBL64925 0.71
SCHEMBL29407705 0.71
SCHEMBL2078432 0.71 AXL (0.48) AXLJAK2JAK3DYRK1ANUDT1
SCHEMBL1704740 0.71 RPS6KA5 (0.37) ADORA2ARPS6KA5
SCHEMBL7016693 0.71 XDH (0.47) ADORA2ARPS6KA5CCNT1CCNA2CDK2
SCHEMBL1566406 0.71 AXL (0.53) ADORA2AADORA1CCR8KMT2AAXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260027119-A1 INHIBITORS OF CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE II AND THEIR USES UNIV JOHNS HOPKINS (US) 2026-01-29 US disclosed
WO-2024020092-A2 INHIBITORS OF CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE II AND THEIR USES THE JOHNS HOPKINS UNIVERSITY (US) 2024-01-25 WO disclosed
US-20230072683-A1 PYRIDO-PYRIMIDIN DERIVATIVES AND PHARMACEUTICAL COMPOSITION, FOR USE IN PREVENTING OR TREATING PI3 KINASE RELATED DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT BORYUNG PHARMACEUTICAL CO., LTD. (KR) 2023-03-09 US disclosed
US-8975250-B2 5 oxo-5,8-dihydropyrido[2,3-d]pyrimidine derivatives as CaMKII kinase inhibitors for treating cardiovascular diseases SANOFI (FR) 2015-03-10 US disclosed
US-8975250-B2 5 oxo-5,8-dihydropyrido[2,3-d]pyrimidine derivatives as CaMKII kinase inhibitors for treating cardiovascular diseases SANOFI (FR) 2015-03-10 US disclosed
US-8975250-B2 5 oxo-5,8-dihydropyrido[2,3-d]pyrimidine derivatives as CaMKII kinase inhibitors for treating cardiovascular diseases SANOFI (FR) 2015-03-10 US disclosed
EP-2521726-B1 5-OXO-5,8-DIHYDROPYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS CAMKII KINASES INHIBITORS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES SANOFI SA (FR) 2013-12-18 EP disclosed
CN-102791710-A 5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine derivatives as CaMKII kinase inhibitors for treating cardiovascular diseases SANOFI AVENTIS 2012-11-21 CN disclosed
CN-102791710-A 5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine derivatives as CaMKII kinase inhibitors for treating cardiovascular diseases SANOFI AVENTIS 2012-11-21 CN disclosed
EP-2521726-A1 5-OXO-5, 8-DIHYDROPYRIDO [2, 3-D]PYRIMIDINE DERIVATIVES AS CAMKII KINASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES SANOFI (FR) 2012-11-14 EP disclosed
US-4526964-A Intermediates useful in producing 5-deaza analogs of folic acid and aminopterin SOUTHERN RESEARCH INSTITUTE (US) 1985-07-02 US disclosed
US-4431805-A ANTICARCINOGENIC AGENTS; LEUKEMIA; REDUCTASE INHIBITORS; FOLIC ACID ANTAGONISTS SOUTHERN RESEARCH INSTITUTE (US) 1984-02-14 US disclosed
EP-0075880-A2 Pyrido (2,3-d) pyrimidines Southern Research Institute (US) 1983-04-06 EP disclosed
US-RE30024-E ANTIALLERGENS STERLING DRUG INC. (US) 1979-06-05 US disclosed
US-4118571-A ANTIALLERGENS STERLING DRUG INC. (US) 1978-10-03 US disclosed
US-4103011-A BACTERICIDES DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 1978-07-25 US disclosed
US-4086233-A ANTIALLERGENS STERLING DRUG INC. (US) 1978-04-25 US disclosed
US-4032523-A ANTIALLERGENS STERLING DRUG INC. (US) 1977-06-28 US disclosed
US-4018770-A ANTIALLERGENS STERLING DRUG INC. (US) 1977-04-19 US disclosed
US-3992380-A 5,8-Dihydro-5-oxo-2-(4-or 3-pyridinyl)pyrido[2,3-d]pyrimidine-6-carboxylic acids and esters STERLING DRUG INC. (US) 1976-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260027119-A1 INHIBITORS OF CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE II AND THEIR USES CAMKK1, CAMK2B, CAMKK2 ADORA2A 892/4885ADORA1 1072/4885CCR8 4721/4885
US-20230072683-A1 PYRIDO-PYRIMIDIN DERIVATIVES AND PHARMACEUTICAL COMPOSITION, FOR USE IN PREVENTING OR TREATING PI3 KINASE RELATED DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT PIK3CA, PDXK, PIK3CD ADORA2A 1200/4885ADORA1 775/4885CCR8 2502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.